Nanoform Finland Plc and Celanese Corporation provided an update on their collaboration to evaluate the synergies between their respective technologies in the field of nanoparticle-enabled drug delivery. Together, the API nanoparticles produced through Nanoform's CESS® technology and the Celanese VitalDose® EVA copolymer delivery technology for drug-eluting implants have the potential to enable enhanced sustained release properties by reducing the initial burst release of a drug, which is a persistent challenge in high drug load implants. The increased drug load enabled by the nano formed particles also allows smaller implants with sustained release properties to be developed.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.155 EUR | +6.16% | -15.16% | +35.96% |
Apr. 11 | Nanoform Finland to Deliver Nanomedicine Technology to Japan | MT |
Apr. 11 | Nanoform Enters Exclusive Partnership with CBC to Bring Best-In-Class Nanomedicine Technology to Japan | CI |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
154.5 USD | +0.85% | +0.03% | 17.24B | ||
2.155 EUR | +6.16% | -15.16% | 197M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+35.96% | 197M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- NANOFH Stock
- News Nanoform Finland Oyj
- Nanoform and Celanese Demonstrate Enhanced Drug Delivery Through the Power of Smaller Implants